主要文件

查看所有文档

SML1103

恩替卡韦

Name: 恩替卡韦
Brand: SIGMA

≥98% (HPLC), Nucleic acid synthesis inhibitor, powder

别名:

2-氨基-1,9-二氢-9-[（1S，3R，4S）-4-羟基-3-（羟甲基）-2-亚甲基环戊基] -6H-嘌呤-6-酮, 2-氨基-9-[（（1S，3R，4S）-4-羟基-3-羟甲基-2-亚甲基-环戊基] -3,9-二氢嘌呤-6-酮, BMS 200475, SQ 34,676

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₂H₁₅N₅O₃

化学文摘社编号:

142217-69-4

分子量:

277.28

UNSPSC Code:

51111800

PubChem Substance ID:

329825478

NACRES:

NA.77

MDL number:

MFCD11046562

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

恩替卡韦, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +25 to +40°, c = 0.2 in H₂O

storage condition

desiccated

color

white to beige

solubility

H₂O: 0.5 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](CO)C3=C)C=N2)NC(N)=N1

InChI

1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1

InChI key

QDGZDCVAUDNJFG-FXQIFTODSA-N

说明

Biochem/physiol Actions

恩替卡韦被用作治疗慢性乙型肝炎病毒（CHB）携带的拉米夫定难治性患者的有效药物（每日1 mg剂量）。

恩替卡韦是一种抗病毒鸟嘌呤类似物，可在病毒复制过程中抑制逆转录、DNA复制和转录。恩替卡韦可用于治疗乙型肝炎。

恩替卡韦是一种抗病毒鸟嘌呤类似物，可抑制逆转录、DNA复制和转录。

pictograms

GHS08,GHS07

signalword

Warning

hcodes

H302,H351

pcodes

P202 - P264 - P270 - P280 - P301 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Observation of therapeutic effect of 125I seed implantation combined with chemotherapy and antiviral therapy on HBV-related liver cancer.

Yunjian Zeng et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24(4), 1414-1419 (2019-10-28)

To investigate the therapeutic effect of 125I seed implantation combined with chemotherapy and antiviral therapy on hepatitis B virus (HBV)-related liver cancer. A total of 126 patients with HBV-related liver cancer were selected and divided into observation group (n=63) and

Entecavir therapy for lamivudine?refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.

Sherman M, et al.

Hepatology, 48(1), 99-108 (2008)

Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.

Wei Wei et al.

Cancer communications (London, England), 38(1), 61-61 (2018-10-12)

The optimal strategy for adjuvant therapy after curative resection for hepatocellular carcinoma (HCC) patients with solitary tumor and microvascular invasion (MVI) is controversial. This trial evaluated the efficacy and safety of adjuvant transcatheter arterial chemoembolization (TACE) after hepatectomy versus hepatectomy

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML1103-50MG	04061832636054
SML1103-10MG	04061832636047